16-2-4　ⓔ文献

  1. Rask–Madsen C, King GL: Vascular complications of diabetes: mechanisms of injury and protective factors. Cell Metab, 2013; 17: 20–33.

  2. Kashiwagi A, Nishio Y, et al: Pyruvate improves deleterious effects of high glucose on activation of pentosephosphate pathway and glutathione redox cycle in endothelial cells. Diabetes, 1997; 46: 2088–2095.

  3. Tominaga M, Eguchi H, et al: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care, 1999; 22: 920–924.

  4. Yau JW, Rogers SL, et al: Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care, 2012; 35: 556–564.

  5. Kawasaki R, Tanaka S, et al: Incidence and progression of diabetic retinopathy in Japanese adults with type 2 diabetes: 8 year follow–up study of the Japan Diabetes Complications Study (JDCS). Diabetologia, 2011; 54: 2288–2294.

  6. Ohkubo Y, Kishikawa H, et al: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non–insulin–dependent diabetes mellitus: a randomized prospective 6–year study. Diabetes Res Clin Pract, 1995; 28: 103–117.

  7. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long–term complications in insulin–dependent diabetes mellitus. N Engl J Med, 1993; 329: 977–986.

  8. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 1998; 317: 703–713.

  9. ACCORD Study Group; ACCORD Eye Study Group: Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med, 2010; 363: 233–244.

  10. Kimmelstiel P, Wilson C: Intercapilary lesions in the glomeruli of the kidney. Am J Pathos, 1936; 12: 83–97.

  11. Yokoyama H, Kawai K, et al: Microalbuminuria is common in Japanese type 2 diabetic patients: a nationwide survey from the Japan Diabetes Clinical Data Management Study Group (JDDM 10). Diabetes Care, 2007; 30: 989–992.

  12. Katayama S, Moriya T, et al: Japan Diabetes Complications Study Group. Low transition rate from normo–and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals: the Japan Diabetes Complications Study (JDCS). Diabetologia, 2011; 54: 1025–1031.

  13. Perkovic V, de Zeeuw D, et al: Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol, 2018; 6: 691–704.

  14. Mann JFE, Ørsted DD, et al: Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med, 2017; 377:839–848.

  15. Wanner C, Heerspink HJL, et al: Investigators. Empagliflozin and kidney function decline in patients with type 2 diabetes: A slope analysis from the EMPA-REG OUTCOME Trial. J Am Soc Nephrol, 2018; 29: 2755–2769.

  16. Perkovic V, Jardine MJ, et al: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med, 2019; 380: 2295–2306.

  17. Lewis EJ, Hunsicker LG, et al: Renoprotective effect of the angiotensin–receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 2001; 345: 851–860.

  18. Brenner BM, Cooper ME, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 2001; 345: 861–869.

  19. Araki S, Haneda M, et al: Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes, 2005; 54: 2983–2987.

  20. Smith AG, Russell J, et al: Lifestyle intervention for pre–diabetic neuropathy. Diabetes Care, 2006; 29: 1294–1299.

  21. 佐藤　譲，馬場正之，他：糖尿病性神経障害の発症頻度と臨床診断におけるアキレス腱反射の意義―東北地方15,000人の実態調査―．糖尿病，2007; 50: 799–806．

  22. 真田　充，安田　斎：糖尿病性神経障害の疫学．日本臨牀，2010; 68(supple9): 538–541.

  23. Stratton IM, Adler AI, et al: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000; 321: 405–412.

  24. Ceriello A, Esposito K, et al: Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes, 2008; 57: 1349–1354.

  25. Stamler J, Vaccaro O, et al: Diabetes, other risk factors, and 12–yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care, 1993; 16: 434–444.

  26. Haffner SM, Leto S, et al: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med, 1998; 339: 229–234.

  27. Ueki K, Sasako T, et al: J–DOIT3 Study Group. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J–DOIT3): an open–label, randomised controlled trial. Lancet Diabetes Endocrinol, 2017; 5: 951–964.

  28. Cholesterol Treatment Trialists’ Collaboration: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta–analysis of data from 170,000 participants in 26 randomized trials. Lancet, 2010; 376: 1670–1681.

  29. Zinman B, Wanner C, et al: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 2015; 373: 2117–2128.

  30. Marso SP, Daniels GH, et al: Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2016; 375: 311–322.

  31. Holman RR, Paul SK, et al: 10–year follow–up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008; 359: 1577–1589.